- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04878770
NMF-CsA-Dupi Trial
Use of the NMF Biomarker as Predictive Diagnostic for Effective Use of Cyclosporine and Dupilumab in the Treatment of Atopic Dermatitis
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Suzanne G.M.A. Pasmans, Prof
- Номер телефона: +31 6 53524299
- Электронная почта: s.pasmans@erasmusmc.nl
Места учебы
-
-
Zuid-Holland
-
Rotterdam, Zuid-Holland, Нидерланды
- Рекрутинг
- Erasmus MC - Sophia Children's Hospital
-
Контакт:
- prof. S.G.M.A. Pasmans, MD PhD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Children and adolescents, aged 2-18 years, with moderate-to-severe atopic dermatitis (diagnosed according to the UK working party criteria)
- Patient and parents/guardians able to participate in the study and willing to give written informed consent
- EASI (Eczema Area Severity Index) ≥ 6 at screening and baseline (corresponding with moderate-to-severe disease)
- IGA (Investigator Global Assessment) ≥ 3 at screening and baseline (corresponding with moderate-to-severe disease)
Exclusion Criteria:
- Children under the age of 2 years and patients older than 18 years
- Contraindication for ciclosporin
- Contraindication for dupilumab
- Patient (or one of the parents/guardians) not willing to be randomized
- Children with a history of any known primary immunodeficiency disorder
- Children with a history of cancer
- EASI < 6 at screening or baseline
- IGA < 3 at screening or baseline
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Активный компаратор: Topical corticosteroids (control)
This group will receive topical corticosteroids.
|
Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis.
In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed.
Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
|
Активный компаратор: Systemic cyclosporine
This group will receive topical corticosteroids and systemic cyclosporin.
|
Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis.
In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed.
Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD. For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months.
Другие имена:
|
Активный компаратор: Systemic dupilumab
his group will receive topical corticosteroids and systemic dupilumab.
|
Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis.
In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed.
Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
DUPIXENT can be used with or without topical corticosteroids.
rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
EASI
Временное ограничение: t = 0, 1 month, 2 months, 3 months and 6 months
|
Change from baseline Eczema Area and Severity Index (0-72) over the course of 6 months, with higher scores meaning worse outcomes.
|
t = 0, 1 month, 2 months, 3 months and 6 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
EASI75
Временное ограничение: t = 1 month, 2 months, 3 months and 6 months
|
Relative reduction of 75% from baseline EASI without the use of rescue medication
|
t = 1 month, 2 months, 3 months and 6 months
|
IGA 0 or IGA 1
Временное ограничение: t = 0, 1 month, 2 months, 3 months and 6 months
|
Proportion of patients that achieved IGA 0 or IGA 1 (Investigator's Global Assessment) without the use of rescue medication.
|
t = 0, 1 month, 2 months, 3 months and 6 months
|
NRS-11 reduction for itch ≥ 4 points
Временное ограничение: t = 0, 1 month, 2 months, 3 months and 6 months
|
Proportion of patients that achieved a reduction ≥4 points on the Numeric Rating Scale-11 (0-10) for itch intensity.
|
t = 0, 1 month, 2 months, 3 months and 6 months
|
POEM
Временное ограничение: t = 0, 1 month, 2 months, 3 months and 6 months
|
Change from baseline in Patient-Oriented Eczema Measure questionnaire (0-28) over the course of 6 months, with higher scores meaning worse outcomes.
|
t = 0, 1 month, 2 months, 3 months and 6 months
|
SCORAD
Временное ограничение: t = 0, 1 month, 2 months, 3 months and 6 months
|
Change from baseline in Scoring Atopic Dermatitis scale (0-103) over the course of 6 months, with higher scores meaning worse outcomes.
|
t = 0, 1 month, 2 months, 3 months and 6 months
|
RECAP
Временное ограничение: t = 0, 1 month, 2 months, 3 months and 6 months
|
Change from baseline in the Recap of Atopic Eczema questionnaire (0-28) over the course of 6 months, with higher scores meaning worse outcomes.
|
t = 0, 1 month, 2 months, 3 months and 6 months
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
CDLQI ≥4 years
Временное ограничение: t = 0, 3 months and 6 months
|
Children's Dermatology Life Quality Index, in the context of a cost-effectiveness analysis
|
t = 0, 3 months and 6 months
|
IDQoL <4 years
Временное ограничение: t = 0, 3 months and 6 months
|
Infants' Dermatitis Quality of Life Index, in the context of a cost-effectiveness analysis
|
t = 0, 3 months and 6 months
|
Emollients and steroid use in frequency and tubes used
Временное ограничение: t = 0, 1 month, 2 months, 3 months, 4 months, 5 months and 6 months
|
In context of a cost-effectiveness analysis: To assess the use of topical medication, including emollients, expressed in number of grams and/or used tubes, and changes therein during systemic treatment.
|
t = 0, 1 month, 2 months, 3 months, 4 months, 5 months and 6 months
|
Healthcare costs related to the treatment of AD
Временное ограничение: Over the course of 6 months
|
In context of a cost-effectiveness analysis: To assess medical specialist care, hospitalization, medication, and other costs directly associated with the treatment and recurrence.
|
Over the course of 6 months
|
Adverse events
Временное ограничение: Over the course of 6 months
|
Adverse events related to therapy as reported at any time during treatment by patient, custodian or investigator.
|
Over the course of 6 months
|
NMF measured via Raman spectroscopy
Временное ограничение: t = - 2 weeks, 0, 3 months and 6 months
|
Natural Moisturizing Factor, to acquire more knowledge about external and internal factors that influence the NMF biomarker
|
t = - 2 weeks, 0, 3 months and 6 months
|
Microbiome profile
Временное ограничение: t = 0, 3 months and 6 months
|
To investigate differences in microbiome profiles between patients with normal vs low NMF, and to investigate changes from baseline in microbiome profile during treatment, periodic swabs of nose, lesional skin, non-lesional skin and faeces will be obtained from patients.
|
t = 0, 3 months and 6 months
|
Humoral blood panel (systemic arms)
Временное ограничение: t = 0, 1 month, 3 months and 6 months
|
Changes in IgE during systemic treatment over the course of 6 months.
|
t = 0, 1 month, 3 months and 6 months
|
Humoral blood panel (topical arm)
Временное ограничение: t = 0 and 6 months
|
Changes in IgE during topical treatment over the course of 6 months.
|
t = 0 and 6 months
|
Cellular blood panel (systemic arm)
Временное ограничение: t = 0, 1 month, 3 months and 6 months
|
Changes in leucocyte differentiation during systemic treatment over the course of 6 months.
|
t = 0, 1 month, 3 months and 6 months
|
FLG null mutations
Временное ограничение: t = 0
|
Genotyping on skin barrier proteins, to acquire more knowledge about external and internal factors that influence atopic dermatitis and the NMF biomarker
|
t = 0
|
Activity of atopy
Временное ограничение: t = 0, 3 months and 6 months
|
The activity of rhinoconjunctivitis, asthma and food allergy examined by a pediatric allergist and pediatric pulmonologist.
|
t = 0, 3 months and 6 months
|
Psychosocial factors (CBCL)
Временное ограничение: t = 0
|
To investigate the influence of psychosocial factors in the patient on pediatric atopic dermatitis as assessed by the CBCL (Child Behaviour Checklist).
Patients are assessed by questions grouped in empirically based syndrome scales: Aggressive Behavior, Anxious/Depressed, Attention Problems, Rule-Breaking Behavior, Somatic Complaints, Social Problems, Thought Problems, Withdrawn/Depressed. Higher percentile scores per scale indicate worse outcomes.
|
t = 0
|
Psychosocial factors (OBVL)
Временное ограничение: t = 0
|
To investigate the influence of psychosocial factors in the family on pediatric atopic dermatitis as assessed by the OBVL (OpvoedingsBelastingVragenLijst / Parenting Stress Questionnaire), with higher percentile scores indicating worse outcomes
|
t = 0
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Кожные заболевания
- Заболевания иммунной системы
- Гиперчувствительность, немедленная
- Генетические заболевания, врожденные
- Кожные заболевания, генетические
- Гиперчувствительность
- Кожные заболевания, экзематозные
- Дерматит
- Дерматит, атопический
- Физиологические эффекты лекарств
- Молекулярные механизмы фармакологического действия
- Противоинфекционные агенты
- Ингибиторы ферментов
- Противоревматические агенты
- Иммунодепрессанты
- Иммунологические факторы
- Дерматологические агенты
- Противогрибковые агенты
- Ингибиторы кальциневрина
- Циклоспорин
- Циклоспорины
Другие идентификационные номера исследования
- MEC-2019-0568
- 2019-003247-30 (Номер EudraCT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Topical corticosteroids
-
Universidad de AntioquiaINNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES (CIDEPRO) и другие соавторыОтозванЛейшманиоз, кожныйКолумбия
-
Stiefel, a GSK CompanyGlaxoSmithKlineЗавершенныйЮношеские угриСоединенные Штаты
-
Lipidor ABРекрутингПсориаз легкой и средней степени тяжестиИндия